4-{[N-(tert-butyloxycarbonyl)-L-phenylalanyl]amino}pyridine | 88932-71-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-{[N-(tert-butyloxycarbonyl)-L-phenylalanyl]amino}pyridine
• 英文别名: tert-butyl N-[(2S)-1-oxo-3-phenyl-1-(pyridin-4-ylamino)propan-2-yl]carbamate
• CAS: 88932-71-2
• 化学式: C₁₉H₂₃N₃O₃
• 分子量: 341.41
• InChiKey: YKSJUEHSWAHCJK-INIZCTEOSA-N

物化性质

• 熔点：
  61-68 °C
• 沸点：
  578.6±50.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  80.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-{[N-(tert-butyloxycarbonyl)-L-phenylalanyl]amino}pyridine 在 N-甲基吗啉 、 盐酸 、 氯甲酸异丁酯 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 (S)-1-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-2-phenyl-1-(pyridin-4-ylcarbamoyl)-ethyl]-amide
  参考文献：
  名称：

  Development of Potent Bifunctional Endomorphin-2 Analogues with Mixed μ-/δ-Opioid Agonist and δ-Opioid Antagonist Properties

  摘要：

  The C terminus of endomorphin-2 (EM-2) analogues (Tyr-Pro-Phe-NH-X) was modified with aromatic, heteroaromatic, or aliphatic groups (X = phenethyl,benzyl, phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, tert-butyl, cyclohexyl, or adamantyl; 3-18) to study their effect on opioid activity. Only 9 (1-naphthyl), 11 (5-quinolyl), 16 (cyclohexyl), and 18 (2-adamantyl) exhibited mu-opioid receptor affinity in the nanomolar range (K-i = 2.41-6.59 nM), which, however, was 3- to 10-fold less than the parent peptide. Replacement of Tyr(1) by Dmt (2',6'-dimethyl-L-tyrosine) (19-32) exerted profound effects: (i) acquisition of high mu-opioid receptor affinity (K-i = 0.11-0.52 nM) except 23 (Ph); (ii) presence of potent functional mu-opioid receptor agonism (IC50 < 1 nM) for 19 ([Dmt(1)]EM-2), 27 (1-naphthyl), 29 (5-quinolyl), and 32 (5-isolquinolyl); (iii) association of weak delta-opioid antagonist activity (pA(2) = 5.41-7.18) except 19 ([Dmt(1)]EM-2), 20 (H), 27 (1-naphthyl), and in particular 29 (5-quinolyl) with its potent delta-agonism (IC50 = 0.62 nM, pA(2) = 5.88); (iv) production of antinociception after ic administration of 32 (5-isoquinolyl) in mice, a bioactivity absent in the corresponding Tyr(1) analogue (14); and (v) preferential cis orientation (cis/trans = 3:2 to 7:3) at the Dmt-Pro amide bond, in contrast to the Tyr-Pro amide trans orientation (cis/trans = 1:2 to 1:3). Thus, [Dmt(1)]EM-2 analogues with hydrophobic C-terminal extensions provide model compounds with potent mu-opioid receptor bioactivity and dual functional agonism.

  DOI：

  10.1021/jm030649p
• 作为产物：
  描述：

  BOC-L-苯丙氨酸 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-{[N-(tert-butyloxycarbonyl)-L-phenylalanyl]amino}pyridine
  参考文献：
  名称：

  Design of Plasma Kallikrein Inhibitors: Functional and Structural Requirements of Plasma Kallikrein Inhibitors.

  摘要：

  合成血浆激肽释放酶（PK）抑制剂反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧甲基苯甲酰胺（PKSI-527）由三个部分组成。尝试用类似物替换每个部分，以提高PKSI-527的效力和选择性。在检测的肽中，反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧基苯甲酰胺（肽16）对PK具有高度选择性，IC50值为2.7μM，与PKSI-527效力相当。

  DOI：

  10.1248/cpb.46.452

文献信息

• Chiral Primary Amine-Polyoxometalate Acid Hybrids as Asymmetric Recoverable Iminium-Based Catalysts
  作者：Jiuyuan Li、Xin Li、Pengxin Zhou、Long Zhang、Sanzhong Luo、Jin-Pei Cheng

  DOI：10.1002/ejoc.200900594

  日期：2009.9

  acid–base assembly of multidentate chiral primary amines and solid polyacids is presented. A suitable structurally distinctive C2-symmetric chiral primary amine (CPA) was identified in this study and the optimal CPA–POM hybrid obtained catalyzed the Diels–Alder cycloaddition of α-substituted acroleins in high yields and fair-to-high selectivity under aqueous conditions. The primary amine in the metal–organic-framework

  提出了一种通过多齿手性伯胺和固体多元酸的酸碱组装固定亚胺有机催化剂的新策略。在本研究中确定了一种合适的结构独特的 C2 对称手性伯胺 (CPA)，获得的最佳 CPA-POM 杂化物在水性条件下以高产率和公平到高的选择性催化 α-取代丙烯醛的 Diels-Alder 环加成反应. 类金属有机骨架 (MOF) 催化剂中的伯胺充当催化中心和多齿碱性中心，而磷钨酸则充当催化剂锚和活性和立体选择性调节剂的双重作用。此外，类 MOF 催化剂表现出高反应性和物理稳定性，因此可以回收和重复使用 6 次，而活性和选择性损失很小。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• Synthesis of pyridine derivatives of L-phenylalanine as antisickling reagents
  作者：Janina Altman、Marian Gorecki、Meir Wilchek、Joseph R. Votano、Alexander Rich

  DOI：10.1021/jm00371a007

  日期：1984.5

  Several bicyclic agents composed of L-phenylalanine coupled to various pyridines were synthesized: 2-, 3-, and 4-(L- phenylalanylamino )pyridine. All three compounds at 3 mM gave positive morphological antisickling effects on homozygous SS cells under reduced O2 tension. Studies on two of these compounds, 2- and 3-(L- phenylalanylamino )pyridine, showed that these agents increase the deoxy-HbS solubility ratio, Cs/ Cs0 , by 14% at 20 mM. Observed changes in the mean corpuscular hemoglobin concentration (MCHC) values of treated cells ranged from 4% at 1.3 mM to 15% at 5.6 mM in compound concentration. Very minor lytic activity was found for treated cells, indicating water uptake is responsible for changes in the MCHC. Further, exposure of sickle cells to a 3 mM concentration of these agents also increased by 6- to 7-fold cellular deformability of a treated erythrocyte population as compared to an untreated one at the same total O2 saturation of 47%. These agents demonstrate the potential of bicyclic compounds composed of a common constituent, L-Phe, in the development toward a viable therapeutic agent.
• Design of Plasma Kallikrein Inhibitors: Functional and Structural Requirements of Plasma Kallikrein Inhibitors.
  作者：Yuko TSUDA、Keiko WANAKA、Mayako TADA、Shosuke OKAMOTO、Akiko HIJIKATA-OKUNOMIYA、Yoshio OKADA

  DOI：10.1248/cpb.46.452

  日期：——

  The synthetic plasma kallikrein (PK) inhibitor trans-4-aminomethylcyclohexanecarbonylphenylalanine-4-carboxymethylanilide (PKSI-527) consists of three parts. Each part was replaced by analogues in an attempt to improve the potency and the selectivity of PKSI-527. Among the peptides examined, trans-4-aminomethylcyclohexanecarbonylphenylalanine-4-carboxyanilide (peptide 16) inhibited PK with a high selectivity and an IC50 value of 2.7μM, being as potent as PKSI-527.

  合成血浆激肽释放酶（PK）抑制剂反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧甲基苯甲酰胺（PKSI-527）由三个部分组成。尝试用类似物替换每个部分，以提高PKSI-527的效力和选择性。在检测的肽中，反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧基苯甲酰胺（肽16）对PK具有高度选择性，IC50值为2.7μM，与PKSI-527效力相当。
• Development of Potent Bifunctional Endomorphin-2 Analogues with Mixed μ-/δ-Opioid Agonist and δ-Opioid Antagonist Properties
  作者：Yoshio Fujita、Yuko Tsuda、Tingyou Li、Takashi Motoyama、Motohiro Takahashi、Yoshiro Shimizu、Toshio Yokoi、Yusuke Sasaki、Akihiro Ambo、Atsuko Kita、Yunden Jinsmaa、Sharon D. Bryant、Lawrence H. Lazarus、Yoshio Okada

  DOI：10.1021/jm030649p

  日期：2004.7.1

  The C terminus of endomorphin-2 (EM-2) analogues (Tyr-Pro-Phe-NH-X) was modified with aromatic, heteroaromatic, or aliphatic groups (X = phenethyl,benzyl, phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, tert-butyl, cyclohexyl, or adamantyl; 3-18) to study their effect on opioid activity. Only 9 (1-naphthyl), 11 (5-quinolyl), 16 (cyclohexyl), and 18 (2-adamantyl) exhibited mu-opioid receptor affinity in the nanomolar range (K-i = 2.41-6.59 nM), which, however, was 3- to 10-fold less than the parent peptide. Replacement of Tyr(1) by Dmt (2',6'-dimethyl-L-tyrosine) (19-32) exerted profound effects: (i) acquisition of high mu-opioid receptor affinity (K-i = 0.11-0.52 nM) except 23 (Ph); (ii) presence of potent functional mu-opioid receptor agonism (IC50 < 1 nM) for 19 ([Dmt(1)]EM-2), 27 (1-naphthyl), 29 (5-quinolyl), and 32 (5-isolquinolyl); (iii) association of weak delta-opioid antagonist activity (pA(2) = 5.41-7.18) except 19 ([Dmt(1)]EM-2), 20 (H), 27 (1-naphthyl), and in particular 29 (5-quinolyl) with its potent delta-agonism (IC50 = 0.62 nM, pA(2) = 5.88); (iv) production of antinociception after ic administration of 32 (5-isoquinolyl) in mice, a bioactivity absent in the corresponding Tyr(1) analogue (14); and (v) preferential cis orientation (cis/trans = 3:2 to 7:3) at the Dmt-Pro amide bond, in contrast to the Tyr-Pro amide trans orientation (cis/trans = 1:2 to 1:3). Thus, [Dmt(1)]EM-2 analogues with hydrophobic C-terminal extensions provide model compounds with potent mu-opioid receptor bioactivity and dual functional agonism.